0001104659-26-082758.txt : 20260710 0001104659-26-082758.hdr.sgml : 20260710 20260710200017 ACCESSION NUMBER: 0001104659-26-082758 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260708 FILED AS OF DATE: 20260710 DATE AS OF CHANGE: 20260710 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HENDERSON MICHAEL THOMAS CENTRAL INDEX KEY: 0001779990 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41740 FILM NUMBER: 261169795 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apogee Therapeutics, Inc. CENTRAL INDEX KEY: 0001974640 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 934958665 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 LETTERMAN DRIVE STREET 2: BUILDING B CITY: SAN FRANCISCO STATE: CA BUSINESS PHONE: 650-394-5230 MAIL ADDRESS: STREET 1: 1 LETTERMAN DRIVE STREET 2: BUILDING B CITY: SAN FRANCISCO STATE: CA FORMER COMPANY: FORMER CONFORMED NAME: Apogee Therapeutics, LLC DATE OF NAME CHANGE: 20230420 4 1 tm2620107-1_4seq1.xml OWNERSHIP DOCUMENT X0609 4 2026-07-08 0 0001974640 Apogee Therapeutics, Inc. APGE 0001779990 HENDERSON MICHAEL THOMAS false C/O APOGEE THERAPEUTICS, INC. 1 LETTERMAN DRIVE, BUILDING B SAN FRANCISCO CA 94129 1 1 0 0 Chief Executive Officer 1 Common Stock 2026-07-08 4 S 0 20000 133.63 D 995987 D Common Stock 2026-07-10 4 G 0 75046 0.00 D 920941 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.52 to $133.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund. /s/ Matthew Batters, as attorney-in-fact for Michael Henderson 2026-07-10